Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One does not lose money until they sell. If they sold, their fault.
What's the question?
Buh BYE
I'm not sure what planet some of you people are from, but when issues are presented to a court, a motion decides what the issues are. As far as I know, the motion was to award NCE. This has nothing to do with the SPA whatsoever. That would be a completely different motion and ruling. Judges will ALWAYS tell the parties to stay on the topic of the motion and the motion only unless there are circumstances that can lead to the motion at hand.
As far as the talk about the judge doing his own investigation.... THAT IS NOT GOING TO HAPPEN. He will rule on the facts presented to him and only that. He does NOT have his own investigative team validating the information presented to him from both sides.
Some of you guys are incredibly wild in your theories.
It will be on NCE ONLY. Yes, he can give it 5 years from judgement day. Unlikely, but a possibility. Hoping he does!!!!!!
Thanks Jason
You could be dead right. It happens all the time in public and private sector.
Is anyone here going to be at the NCE hearing tomorrow?
Anyone remember this from last year? http://us.cnn.com/2014/01/18/health/fish-oil-recovery/index.html?sr=sharebar_twitter
I averaged from $15 down to $2.97. Almost even. I wasn't happy back then, but I picked up an additional 20,000 shares because of it. So I hope to be very happy within a year or two.
BEDMINSTER, NJ and DUBLIN, IRELAND, and MACAO S.A.R, PEOPLE'S REPUBLIC OF CHINA -- (Marketwired) -- 02/26/15 -- Amarin Corporation plc (NASDAQ: AMRN) and Eddingpharm, two pharmaceutical companies focused on the development and commercialization of innovative therapeutics, today announced an exclusive agreement for Eddingpharm to develop and commercialize Vascepa® (icosapent ethyl) in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan for uses that are currently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa.
Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.
The Chinese pharmaceutical market has been growing at an annual rate of approximately 20% during the past ten years and currently is the third largest pharmaceutical market in the world. This trend is expected to continue and enable the territory to surpass Japan as the second largest pharmaceutical market in the world by the end of this decade. The combination of the high prevalence rates of hypertriglyceridemia and large population size suggest that a great number of patients in China would benefit from therapy with Vascepa. To date, there has been no prescription grade pharmaceutical omega-3 product in China, and thus there is a high unmet need for an efficacious and safe product to treat the millions of patients that have related lipid abnormalities.
Vascepa is indicated in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia. Vascepa also demonstrated favorable effects on triglycerides and a spectrum of other lipid, lipoprotein and inflammatory biomarkers in the Phase 3 ANCHOR clinical trial of adult patients with high triglycerides (=200 mg/dL and < 500 mg/dL) despite statin therapy. Vascepa is currently being studied in a multinational cardiovascular outcomes study, the REDUCE-IT study, to evaluate its effectiveness in reducing the prevalence of first major cardiovascular events in a high-risk patient population. REDUCE-IT enrollment of an estimated 8,000 patients is expected to be completed in 2015, with a protocol pre-specified interim data analysis of efficacy and safety results at 60% of targeted events anticipated in 2016 by the independent Data Monitoring Committee (DMC). Completion of the REDUCE-IT study, if not stopped earlier based on the interim analysis by the independent DMC, is expected in 2017 with published results expected to be available in 2018. Successful REDUCE-IT trial results would position Vascepa to be the first and only prescription grade omega-3 product approved for augmentation to statin therapy for cardiovascular risk reduction indications, a potentially multi-billion dollar commercial opportunity in the United States alone, and position Vascepa for a similar indication in China for which the opportunity is also large.
"Vascepa has the potential to occupy a leading position in the substantial worldwide market for prescription omega-3 products," commented John F. Thero, President and Chief Executive Officer of Amarin. "Our agreement with Eddingpharm reflects the culmination of a competitive process and represents a significant step toward commercializing Vascepa in a major market outside the United States. We are very pleased to be collaborating with Eddingpharm. We believe that their team is well suited to successfully introduce Vascepa in China. Eddingpharm has established development and regulatory capabilities and an impressive commercial organization that has launched many innovative products in China. Eddingpharm's successful track record of long-term alliances with leading global pharmaceutical companies gives us confidence in Vascepa's success in China. The agreement also validates the Vascepa and REDUCE-IT investment hypothesis and marks our start at licensing the ex-US rights to Vascepa to leading commercialization partners around the world."
"There is a large unmet need for a high-quality, well-studied and differentiated prescription grade omega-3 product in the Chinese market," commented Xin Ni, Founder, Chairman and Chief Executive Officer of Eddingpharm. "We are delighted that Amarin has entrusted Eddingpharm to develop and commercialize Vascepa in Greater China. Vascepa has significant commercial potential in the rapidly growing Chinese market. Together with Amarin, we are committed to bringing this medicine to millions of patients in the region."
Camber went from 10,300,000 to 12,000,000. They picked up 1.7 million shares since last filing in January 2014.
Jason Williams makes a bold statement. LMAO
I would agree more with this scenario than the original when it comes to our stock. The share price damage will not fly. Please share your update with this board when you receive a response to your complaint. Prepare for disappointment.
I work for the Govt. That is not a valid form under these circumstances.
I totally agree with Invest. Highly doubt we get any type of resonse.
I've never said I was an expert on anything. Just a vested interest with accumulating 25K shares since mid 2012. I watch just about every post on here, but let's be serious. His conspiracy theories are out of line. You know and everyone knows it with the exception of a few.
How many times have his predictions drove PPS in an upward direction? None. Enough said!
Dude, let's face it. Your history has not been all that impressive. Matter of fact, not impressive at all. If you're going to state theories you claim to be factual, just reference it. Kind of like "APA style 101" when citing references for college course work.
How about providing the actual documents showing what you're saying!
Please state the "facts" as to what specifically this has to do with Amarin? Please be specific!!!
And you're assuming this is about Amarin????????
I'm actually paying $13 for a 3 month supply through express-scripts. My insurance is Tricare.
So BB.. Are you saying the FDA should now be issuing NCE to Amarin?
What airfare?????? It's in NYC and they are in Northern NJ.
If the stock price is always right and a predictor, it would have been like that with MNKD before the ADCOM.
Yes. I went back and noticed. Thanks.
They already had 184K shares. They just added 304. No big deal.
What does you FDA "LEAK" say?
Like I said.... After they announce earnings, which will NOT be during trading hours. It's always done BEFORE OR AFTER market hours. The 10K is done AFTER we already see the press release. For someone who posts so much on here, one should expect you to have minimal basic knowledge. Apparently not though. Study up Chica
Yes, after the information is already know to the public. What are you looking to see?
It's always after market close. It will never happen during the trading day.
No person in their right mind would risk telling you something that will land them in jail. You should really stop talking nonsense.
His name is Grant Virgin.
Never argue with the author of "The Pelican Brief"
What does a tobacco case have to do with ours? Please explain your logic?
Is this a prediction or factual numbers?
Is their a copy of that?